Shaalan Beg MD MBA FASCO retweeted
Two great articles in #ASCOConnection on opportunities for volunteering and engagement at @ASCO.
connection.asco.org/do/guide…
connection.asco.org/do/asco-…
Shaalan Beg MD MBA FASCO retweeted
Trastuzumab plus nivolumab with GemCis as 1L
therapy for HER2-positive unresectable BTC: pls 1b/2 trial
@NatureMedicine
doi.org/10.1038/s41591-026-0…
👉ORR 55%, DCR 95%
👉mPFS 10.6 mo, mOS nr
🧐Promising, HERIZON BTC & DESTINY-BTC awaited
Shaalan Beg MD MBA FASCO retweeted
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature @Nature_NPJ
👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine #AI
👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬
👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts.
👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert @oncodaily
nature.com/articles/s41698-0…
Shaalan Beg MD MBA FASCO retweeted
Great perspective from @PauloBergerot in @ASCO Daily News on a critical challenge in #ExerciseOncology: moving beyond the optimal exercise dose to interventions that are feasible, accessible, and sustainable in patients’ everyday lives #ASCOQLTY26
dailynews.ascopubs.org/do/ca…
Shaalan Beg MD MBA FASCO retweeted
Our atlas of young-onset CRC is finally out in @NatureMedicine! We found a unique biology in younger patients that may explain the aggressive nature of this disease. This was a monumental effort with colleagues at @MassGenBrigham and @broadinstitute. @DFarberYoungCRC
Researchers co-led by @KimmieNgMD of @DanaFarber and @DFarberYoungCRC created the largest single-cell atlas of colorectal cancer ever, identifying age-associated differences that may help research into why #colorectalcancer can be more aggressive in younger adults. ➡️bit.ly/4kmBFEl
ASCO Members! You now get full access to ASCO Meetings content 30 days post-meeting. Explore the latest science faster! View content from the 2026 ASCO Annual Meeting: bit.ly/4hXg1DS
Coming soon: An AI-powered agent from ASCO & Google Cloud to simplify your research.
Shaalan Beg MD MBA FASCO retweeted
Dr. @QasimHussainiMD giving an amazing discussion of two studies on #ExerciseOncology presented at @ASCO Quality Care Symposium this morning.
asco.org/quality/program
#ASCOQLTY26 @crisbergerot @PauloBergerot
Shaalan Beg MD MBA FASCO retweeted
Fantastic oral abstract discussion by Dr. @CharlesJiangMD at @ASCO Quality Care Symposium today!
asco.org/quality/program?int…
#ASCOQLTY26 @utswcancer @UTSWMedCenter
Hey, @TimothyJBrownMD, can an F-150 do this?
Tesla unveiled a redesigned Roadster equipped with thrusters that enable it to fly short distances, nearly nine years after it first showed a next-generation version of its electric sports car, and said it would start production in 2028 reut.rs/4zt7Q9A
We have liftoff: Tesla's new Roadster can fly, sort of - Automotive
Shaalan Beg MD MBA FASCO retweeted
Great to see work from @ASCO Quality Care Symposium simultaneously published in @JCO_ASCO today:
“Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial.”
ascopubs.org/doi/pdf/10.1200…
#ASCOQLTY26
Geographical access to clinical trials remains the number one barrier to enrollment.
Look forward to hearing how technology-enabled services are being used by sites to improve access to cancer trials. #ascoqlty26
Growing excitement for the @ASCO Quality Care Symposium (#ASCOQLTY26) this week!
Nice overview of one of the studies on Decentralizing Clinical Trials being presented at the meeting:
dailynews.ascopubs.org/do/de…
@JamesFanWu @crisbergerot @ShaalanBeg
#CancerResearch #ClinicalTrials
Shaalan Beg MD MBA FASCO retweeted
Atezolizumab is now @FDA ✅ off #ATOMIC Ph III, adj mFOLFOX + Atezo vs. mFOLFOX in Stg III dMMR colon ca.
- 3yr DFS 86.4% vs 76.6% (HR 0.50)
- OS not mature
- ⬆️ Gr4 neutropenia with Atezo.
- How much is chemo benefitting? Role of NICHE2?
- @ASCO Plenary!
#gism #OncTwitter
How has teamwork transformed patient outcomes in your practice? Bring Dr. Elizabeth Mittendorf’s @ASCOPres theme—Intentional Teams. Exceptional Care.—to life on the #ASCO27 stage during the ASCO Voices session.
🎙️ Submit your audition by November 13: bit.ly/4ALUHts
Shaalan Beg MD MBA FASCO retweeted
Based off HER2CLIMB-05, Tucatinib is now @FDA ✅ as maintenance for HER2+ mBC, PhIII, THP —> HP +/-Tucatinib
- Improved PFS in all subsets
- mPFS: 24.9mos vs. 16.3mos (HR: 0.64)
- ⬆️ AEs with Tucatinib (LFTs & diarrhea)
#BreastCancer #bcsm #OncTwitter
Shaalan Beg MD MBA FASCO retweeted
We have 3 Anti-Her2 options today for Upper GI adenocarcinoma. Here is the table outlining dose, common toxicities, and clinical pearls in managing these AEs that we touched on during our #ToxCheck discussion with @ShrutiPatelMD & @Sam_Cytryn
#MedTwitter #MedX #OncTwitter
Tox-Check: Anti-Her2 drugs in Upper GI (Esophageal, GE Junction, and Gastric Adenocarcinoma) w/ @ShrutiPatelMD & @Sam_Cytryn
✅ Trastuzumab
✅ Zanidatamab
✅ TDXd
Full 🗣️:
⭐️ oncbrothers.com/toxcheck-her…
⭐️ “Oncology Brothers” podcast
#OncTwitter @OncoAlert @OncUpdates #gism
Shaalan Beg MD MBA FASCO retweeted
Getting ready to present the phase II GRECO-2 trial Tuesday at #ASTRO26. Can’t stop thinking of you, @TaniguchiMD. There is no way I can represent the purple hair like you did, but I’ll do my best to represent the SOD story.
Missing you, brother. RIP.
Shaalan Beg MD MBA FASCO retweeted
⭐️🚨Just published 👉🏼Pleased to share our standout new review 👉🏼published in @TheLancet @eClinicalMed 👉🏼led by 3 amazing rising stars ⭐️ @JiaJennyLiu @niamhjcoleman @JulianaRBeal
👉🏼“Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and real‑world implementation.”
👉🏼 Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin. The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies.
⭐️Such a delight to work with & mentor this dream team 👉🏼their clarity, rigor, and vision shine through every section 🎯🔥
@OncoAlert @oncodaily @OncBrothers
thelancet.com/journals/eclin…
Shaalan Beg MD MBA FASCO retweeted
🚨Another big win for #precisionmedicine
🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma.
⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx
“Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram
👉🏼Link to FDA approval fda.gov/drugs/resources-info…
👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdisco…
📣Super thrilled to share our paper on RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations & Resistance Mutations, published in @CD_AACR !
👉🏼Huge thanks to team at Cancer Discovery & @AACR for making the front page & the entire paper so visually appealing 👏🏼#PrecisionMedicine 🧬🎯#cancerresearch @OncoAlert @ElizSMcKenna @Relay_Tx
@TaliLev123
👉🏼Free Link: tinyurl.com/yfffae53
We are witnessing the most exciting period of drug development in oncology.
There's a lot of discussion on the FDA's Accelerated Approval pathway.
Who should be eligible to receive AA?
When should approvals be withdrawn?
We tackle this #onlyoncologistsinthebuilding 🔎🔎🕵🏻♂️
here's a link to the full episode please watch and subscribe to our channel!
👇🏻👇🏻
youtu.be/NCkbux-txy4?si=tXnQ…










































